Ucb S A (UCBJF) 71.1200 $UCBJF Dr. Reddy's (RDY)

New Post Public Reply Private Reply Replies (0) Message Board

May 17, 2015 at 4:28 PM

Ucb S A (UCBJF) 71.1200 $UCBJF

Dr. Reddy's (RDY) Earnings and Revenues Rise in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 13, 9:00AM CDT
Dr. Reddy's Laboratories (RDY) reported fourth-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 49 cents, up 8.9% from the year-ago quarter.
SUPN: 13.13 (-0.29), RDY: 55.31 (+0.46)

Immunomedics (IMMU) Provides Update on Lead ADC Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 1:45PM CDT
Immunomedics, Inc. (IMMU) provided an update on its lead ADC candidate, sacituzumab govitecan.
CRMD: 6.38 (-0.06), BIIB: 391.24 (-3.11), IMMU: 4.12 (+0.05)

UCB to Sell Indian Established Brands Portfolio to Dr. Reddy's - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 02, 1:40PM CDT
UCB S.A. (UCBJF) will sell its established brands portfolio in India, to Dr. Reddy's Laboratories Ltd. to focus on core business.
CYTK: 5.96 (-0.06), LCI: 52.60 (-0.73), RDY: 55.31 (+0.46)

Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), OSIR: 17.29 (-0.18), ACOR: 30.04 (+0.14), HSP: 88.10 (-0.08), AGN: 240.22 (+2.88), MDVN: 122.90 (-0.47), ESRX: 87.37 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ARNA: 4.25 (unch), REGN: 489.01 (-2.42), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ALKS: 60.00 (unch), MNKD: 3.99 (+0.36), OREX: 5.01 (unch), NVO: 56.75 (+0.06), ISIS: 62.55 (+0.10), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), PBYI: 177.01 (+6.34), NVS: 103.75 (-0.15)

Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Arpita Dutt - Zacks Investment Research - Tue Mar 17, 11:45AM CDT
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
BIIB: 391.24 (-3.11), ACT: 296.60 (-0.86), VRX: 224.63 (+1.81), PCYC: 255.42 (-0.50), OSIR: 17.29 (-0.18), ACOR: 30.04 (+0.14), HSP: 88.10 (-0.08), AGN: 240.22 (+2.88), MDVN: 122.90 (-0.47), ESRX: 87.37 (-0.09), SHPG: 254.45 (+3.99), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ARNA: 4.25 (unch), REGN: 489.01 (-2.42), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), AMGN: 162.36 (+0.38), MYL: 70.67 (-0.86), LLY: 72.90 (-0.16), BMY: 67.64 (+0.19), GSK: 44.77 (-0.22), ALKS: 60.00 (unch), MNKD: 3.99 (+0.36), OREX: 5.01 (unch), NVO: 56.75 (+0.06), ISIS: 62.55 (+0.10), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), MRK: 60.23 (+0.45), PBYI: 177.01 (+6.34), NVS: 103.75 (-0.15)

UCB's Neupro Positive in Parkinson's Disease Study in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:58PM CST
UCB (UCBJF) announced positive top-line results from two phase III studies on Neupro for early- and advanced-stage Parkinson's disease in Chinese patients.
LCI: 52.60 (-0.73), SCMP: 15.94 (-0.01), BIOD: 1.13 (unch)

Week In Review: WuXi NextCode Leads $15 Million Financing In Claritas Genomics
ChinaBio Today - at Seeking Alpha - Sun Feb 08, 3:46AM CST
Deals and Financings WuXi NextCODE Genomics, the newly formed genomic analysis division of China CRO/CMO WuXi PharmaTech (NYSE: WX ), led a $15 million Series B financing in Claritas Genomics (see story ). Claritas is a Boston-based lab that...
MRK: 60.23 (+0.45), WX: 43.34 (-0.57)

UCB's New Epilepsy Drug Under Review in the U.S., EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 6:00PM CST
UCB S.A. (UCBJF) announced that its investigational antiepileptic candidate, brivaracetam, has been accepted for review in the U.S. and the EU.
BCRX: 10.75 (+0.20), AMGN: 162.36 (+0.38), BIOD: 1.13 (unch)

Immunomedics Reports Data on Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:05PM CST
Immunomedics, Inc., (IMMU) announced data from its lead investigational antibody-drug conjugate (ADC) sacituzumab govitecan from a phase I/II study.
IMMU: 4.12 (+0.05), PFE: 33.99 (+0.05), BIOD: 1.13 (unch)

UCB-Neuropore Collaborate for Parkinson's Disease Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 1:10PM CST
UCB S.A. (UCBJF) and Neuropore Therapies Inc. entered into a collaboration agreement for the development and commercialization of Parkinson's disease related therapies.
LCI: 52.60 (-0.73), ENDP: 85.35 (+0.33), BIOD: 1.13 (unch)

UCB Initiates Phase III Psoriasis Study on Cimzia with Dermira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 09, 4:05PM CST
UCB S.A. (UCBJF) and Dermira finished dosing the first set of patients in a phase III development program on Cimzia for moderate-to-severe chronic plaque psoriasis.
SHPG: 254.45 (+3.99), AMGN: 162.36 (+0.38), NVS: 103.75 (-0.15)

Immunomedics: Under-Followed Company With Robust Pipeline And Huge Growth Potential
Bridging the Gap - at Seeking Alpha - Fri Dec 26, 4:17PM CST

IMMU: 4.12 (+0.05)

UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 52.60 (-0.73), VRX: 224.63 (+1.81), SCMP: 15.94 (-0.01)

UCB Reports Phase III Data on Epilepsy Drug, To File in 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 1:50PM CST
UCB SA (UCBJF) announced positive primary efficacy and safety data from its latest phase III study on its epilepsy candidate, brivaracetam.
LCI: 52.60 (-0.73), VRX: 224.63 (+1.81), SCMP: 15.94 (-0.01)

UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 44.44 (-0.38), VRX: 224.63 (+1.81), SCMP: 15.94 (-0.01)

Immunomedics' Veltuzumab Receives Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 3:20PM CST
Immunomedics' (IMMU) anti-CD20 antibody, veltuzumab, was granted an orphan drug status in the U.S. for the treatment of pemphigus.
BIIB: 391.24 (-3.11), IMMU: 4.12 (+0.05)

Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 296.60 (-0.86), QLTI: 3.72 (+0.03), VRX: 224.63 (+1.81), AGN: 240.22 (+2.88), SHPG: 254.45 (+3.99), AUXL: 36.47 (-0.06), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), ICPT: 306.23 (-0.84), TEVA: 60.23 (-0.99), NVS: 103.75 (-0.15)

Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 296.60 (-0.86), QLTI: 3.72 (+0.03), VRX: 224.63 (+1.81), AGN: 240.22 (+2.88), SHPG: 254.45 (+3.99), AUXL: 36.47 (-0.06), ABBV: 65.99 (+0.02), SNY: 50.52 (-0.27), ABT: 48.71 (+0.04), ENDP: 85.35 (+0.33), AKRX: 41.50 (-0.08), PFE: 33.99 (+0.05), INCY: 106.86 (+0.08), SLXP: 172.96 (+0.15), MYL: 70.67 (-0.86), AMGN: 162.36 (+0.38), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), BMY: 67.64 (+0.19), ACHN: 9.57 (+0.05), MRK: 60.23 (+0.45), AZN: 69.29 (-0.81), ICPT: 306.23 (-0.84), TEVA: 60.23 (-0.99), NVS: 103.75 (-0.15)

Will Catalyst Pharmaceuticals' (CPRX) Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:30PM CST
Catalyst Pharmaceuticals Inc, Inc. (CPRX) is expected to report third-quarter 2014 results on Nov 13.
MNK: 123.83 (-0.48), BMRN: 122.78 (+0.13), CPRX: 3.32 (-0.02)

UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 52.60 (-0.73), LLY: 72.90 (-0.16), GSK: 44.77 (-0.22), NVS: 103.75 (-0.15)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...